Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice. (Q54601392)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21435405

Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice. (English)

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21435405

1 reference

based on heuristic

inferred from title

breast neoplasm

1 reference

based on heuristic

inferred from title

Jedd D. Wolchok

4

object named as

Jedd D Wolchok

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21435405

author name string

Francesca Orlandi

1

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21435405

José A Guevara-Patiño

2

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21435405

Taha Merghoub

3

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21435405

Alan N Houghton

5

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21435405

Polly D Gregor

6

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21435405

language of work or name

0 references

publication date

22 March 2011

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21435405

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21435405

29

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21435405

20

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21435405

3646-3654

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21435405

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

HER2 therapy: molecular mechanisms of trastuzumab resistance.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Xenogeneic DNA immunization in melanoma models for minimal residual disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

DNA fusion gene vaccines against cancer: from the laboratory to the clinic.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Mechanisms of immunization against cancer using chimeric antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Immune recognition of self in immunity against cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic m

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Antibody and CD8+ T cell responses against HER2/neu required for tumor eradication after DNA immunization with a Flt-3 ligand fusion vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Shared antigenic epitopes and pathobiological functions of anti-p185(her2/neu) monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Tumor immunity and autoimmunity induced by immunization with homologous DNA

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

A method that allows easy characterization of tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

CD14 regulates the dendritic cell life cycle after LPS exposure through NFAT activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Trastuzumab (Herceptin) enhances class I-restricted antigen presentation recognized by HER-2/neu-specific T cytotoxic lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Insertion of the DNA for the 163-171 peptide of IL1beta enables a DNA vaccine encoding p185(neu) to inhibit mammary carcinogenesis in Her-2/neu transgenic BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.017

7 January 2021

Identifiers

10.1016/J.VACCINE.2011.03.017

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21435405

1 reference

Europe PubMed Central

1 June 2018

http://europepmc.org/abstract/MED/21435405

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54601392&oldid=1775335088"